Synthetic Lethality
Listed on 2026-01-01
-
Healthcare
-
Research/Development
Research Scientist
At Gordion, we consider all tumor mutations found in Exome and in the Dark Genome. 98% of mutations are found in the Dark Genome, but these are typically ignored in drug program design.
Synthetic LethalityA gene mutation results in other genes becoming essential for tumor survival, a phenomenon called Synthetic Lethality. Inhibition of a Synthetic Lethal gene will be toxic to cancer cells but not to normal cells.
Synthetic Lethality between gene A and B occurs when loss of both genes leads to cell death.
RNAi and CRISPR screens identify synthetic lethal dependenciesScreening is used to identify Synthetic Lethal drug targets. However, experiments based on cell lines have unknown translatability into clinical efficacy.
As a result, many drugs that show promise in pre-clinical phases fail in clinical trials.
Cancer dependencies delivered by mother natureGordion’s AI model was trained on thousands of cancer genomes, analyzing dozens of millions of mutations. Patterns of alterations reveal Synthetic Lethal genes relevant to real tumor biology.
Patient-derived Synthetic Lethality dependencies have a higher chance of delivering clinical trial success.
Synthetic LethalomeAn atlas of Synthetic Lethal genes for all tumor types.
Contact us If you want to power your drug program with insights from real tumor nature’s experimentsGordion Bioscience Inc.
245 Main St, Cambridge
MA 02142, US
(If this job is in fact in your jurisdiction, then you may be using a Proxy or VPN to access this site, and to progress further, you should change your connectivity to another mobile device or PC).